investors & media

There are currently no events to display.

corporate profile

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. We’re putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent β-thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing. bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland.

stock quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

press releases

10/2/2020

European Medicines Agency will evaluate eli-cel MAA under accelerated assessment CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2020-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for its

Read more
9/28/2020

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6 , at 2:00 p.m. ET . To access the live webcast of bluebird bio’s presentation,

Read more
9/23/2020

EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 23, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease

Read more